Abstract
For the last 20 years the classic treatment for relapsing remitting multiple sclerosis was based on injectable disease-modifying drugs, interferon-β and glatiramer acetate (copaxone). Currently, new disease-modifying drugs have been added to the clinician's arsenal with similar and even improved efficacy and safety profiles. Some of these drugs are given orally and are recommended as first line treatment. In this review we will discuss the various innovative and emerging disease-modifying drugs including the method of administration, mechanism of action, efficacy, safety and major side effects.
| Original language | English |
|---|---|
| Pages (from-to) | 686-662 |
| Number of pages | 25 |
| Journal | Harefuah |
| Volume | 153 |
| Issue number | 11 |
| State | Published - 1 Nov 2014 |
| Externally published | Yes |